[go: up one dir, main page]

MX2018007680A - Acidos nucleicos que codifican secuencias repetitivas de aminoacidos ricas en residuos de prolina y alanina que tienen secuencias nucleotidicas con baja repetitividad. - Google Patents

Acidos nucleicos que codifican secuencias repetitivas de aminoacidos ricas en residuos de prolina y alanina que tienen secuencias nucleotidicas con baja repetitividad.

Info

Publication number
MX2018007680A
MX2018007680A MX2018007680A MX2018007680A MX2018007680A MX 2018007680 A MX2018007680 A MX 2018007680A MX 2018007680 A MX2018007680 A MX 2018007680A MX 2018007680 A MX2018007680 A MX 2018007680A MX 2018007680 A MX2018007680 A MX 2018007680A
Authority
MX
Mexico
Prior art keywords
nucleic acid
amino acid
repetitive
proline
low
Prior art date
Application number
MX2018007680A
Other languages
English (en)
Inventor
Binder Uli
Achatz Stefan
Skerra Arne
Original Assignee
Xl Protein Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xl Protein Gmbh filed Critical Xl Protein Gmbh
Publication of MX2018007680A publication Critical patent/MX2018007680A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/68—Stabilisation of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con una molécula de ácidos nucleicos que comprende una secuencia nucleotídica con baja repetitividad que codifica una secuencia repetitiva de aminoácidos rica en prolina/alanina. El polipéptido codificado comprende una secuencia repetitiva de aminoácidos que forma una espira aleatoria. La molécula de ácidos nucleicos que comprende las secuencias nucleotídicas con baja repetitividad puede comprender además, una secuencia nucleotídica que codifica una proteína biológica o farmacológicamente activa. Además, la presente invención proporciona medios y métodos de selección para identificar la molécula de ácidos nucleicos que comprende la secuencia nucleotídica con baja repetitividad. La presente invención también se relaciona con un método para preparar las moléculas de ácidos nucleicos. También se proporcionan en el presente documento métodos para preparar el polipéptido codificado o conjugados del fármaco con el polipéptido codificado utilizando las moléculas de ácidos nucleicos proporcionadas en el presente documento. El conjugado del fármaco puede comprender una proteína biológica o farmacológicamente activa o un fármaco de molécula pequeña. También se proporcionan en el presente documento vectores y hospederos que comprenden tales moléculas de ácidos nucleicos.
MX2018007680A 2015-12-22 2016-12-22 Acidos nucleicos que codifican secuencias repetitivas de aminoacidos ricas en residuos de prolina y alanina que tienen secuencias nucleotidicas con baja repetitividad. MX2018007680A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15202093 2015-12-22
PCT/EP2016/082407 WO2017109087A1 (en) 2015-12-22 2016-12-22 Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences

Publications (1)

Publication Number Publication Date
MX2018007680A true MX2018007680A (es) 2018-11-14

Family

ID=55129435

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007680A MX2018007680A (es) 2015-12-22 2016-12-22 Acidos nucleicos que codifican secuencias repetitivas de aminoacidos ricas en residuos de prolina y alanina que tienen secuencias nucleotidicas con baja repetitividad.

Country Status (19)

Country Link
US (1) US11401305B2 (es)
EP (2) EP3394266B1 (es)
JP (1) JP7065772B2 (es)
KR (1) KR102654180B1 (es)
CN (1) CN109153996B (es)
AU (1) AU2016378646B2 (es)
BR (1) BR112018012784A2 (es)
CA (1) CA3005115A1 (es)
DK (1) DK3394266T3 (es)
EA (1) EA201891127A1 (es)
ES (1) ES2877539T3 (es)
HU (1) HUE055267T2 (es)
IL (1) IL259352B (es)
LT (1) LT3394266T (es)
MX (1) MX2018007680A (es)
PL (1) PL3394266T3 (es)
SG (1) SG11201803958WA (es)
SI (1) SI3394266T1 (es)
WO (1) WO2017109087A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
WO2015105955A1 (en) 2014-01-08 2015-07-16 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
CN111406071B (zh) * 2017-11-16 2024-01-16 成都硕德药业有限公司 Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途
US11548931B2 (en) 2017-11-16 2023-01-10 Xl-Protein Gmbh PASylated VEGFR/PDGFR fusion proteins and their use in therapy
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
US12016889B2 (en) 2018-02-23 2024-06-25 9 Meters Biopharma, Inc. Compositions and methods for treating or preventing intestinal paracellular permeability
KR102209198B1 (ko) * 2019-04-02 2021-02-02 주식회사 바이오앱 식물에서의 발현이 최적화된 재조합 이리신 유전자 및 이를 이용한 재조합 이리신 단백질의 생산 방법
CN110038120B (zh) * 2019-04-02 2022-12-23 河南师范大学 豹蛙抗瘤酶融合蛋白作为治疗肿瘤药物的应用
US12431219B2 (en) * 2019-04-15 2025-09-30 Bruker Daltonics GmbH & Co. KG Methods for determining isomeric amino acid residues of proteins and peptides
WO2020227341A1 (en) * 2019-05-06 2020-11-12 9 Meters Biopharma, Inc. Compositions and methods for treating sjogren's syndrome
TWI878368B (zh) 2019-10-25 2025-04-01 愛爾蘭商爵士製藥愛爾蘭公司 重組ｌ—天冬醯胺酸酶
KR20230124637A (ko) 2020-12-22 2023-08-25 엑스엘-프로테인 게엠베하 구조적으로 무질서한 서열에 대해 특이적인 항체
AU2022272733A1 (en) * 2021-05-14 2023-11-30 Antlia Bioscience, Inc. Modified b-type natriuretic peptide
CN113340864B (zh) * 2021-06-07 2023-04-07 郑州轻工业大学 基于mef效应二次放大ins信号的适体传感器及其制备方法和应用
CN114470170B (zh) * 2022-02-22 2023-09-19 广州新济药业科技有限公司 一种司美格鲁肽可溶性微针组合物及其制备方法
JP2025529925A (ja) 2022-08-26 2025-09-09 エスリス ゲーエムベーハー 安定な脂質またはリピドイドナノ粒子懸濁液
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins
KR20250121363A (ko) * 2022-12-08 2025-08-12 인스메드 인코포레이티드 우리카아제 접합체 및 이의 사용 방법
CN115851667B (zh) * 2023-01-17 2026-01-30 陕西科技大学 一种调控重组核酸酶活性的方法
WO2025045767A1 (en) 2023-08-25 2025-03-06 Ethris Gmbh Stabilized lipid and lipidoid nanoparticle formulations with specific surfactant properties for enhanced pharmaceutical applications
WO2025088192A1 (en) 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for the coupling of di(alkyl)amines to polypeptides
WO2025088193A1 (en) 2023-10-27 2025-05-01 Xl-Protein Gmbh Methods for efficient recombinant production of polypeptides
WO2025233381A1 (en) 2024-05-07 2025-11-13 Technische Universität München, in Vertretung des Freistaates Bayern Enzymes that eliminate pyrimidine and/or purine nucleosides for treating cancer
CN118979069B (zh) * 2024-07-31 2025-03-18 广东省农业科学院植物保护研究所 Chorion protein 36蛋白在调控雌性瓜实蝇生殖中的应用
CN119162200B (zh) * 2024-11-04 2025-11-11 福建农林大学 一种水稻新鲜种子抗穗发芽OsRDR3基因及其InDel标记与应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
CA2225460A1 (en) 1995-06-23 1997-01-09 Winston Campbell Patterson Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US7378506B2 (en) 1997-07-21 2008-05-27 Ohio University Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
US20060252120A1 (en) 2003-05-09 2006-11-09 Kieliszewski Marcia J Synthetic genes for plant gums and other hydroxyproline-rich glycoproteins
MX2008015213A (es) 2006-05-30 2008-12-09 Dow Global Technologies Inc Metodo de optimizacion de codon.
AU2008266448B2 (en) 2007-06-21 2013-06-13 Technische Universitat Munchen Biological active proteins having increased in vivo and/or vitro stability
BR112012029577B1 (pt) 2010-05-21 2022-04-12 Xl-Protein Gmbh Conjugado de fármaco compreendendo polipeptídeos helicoidais randômicos prolina/alanina biossintéticos, e composição farmacêutica ou diagnóstica
EP3113792B1 (en) 2014-03-05 2018-12-05 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with increased duration of effect
KR102727396B1 (ko) 2017-06-21 2024-11-08 재즈 파마슈티칼즈 아일랜드 리미티드 변형된 l-아스파라기나아제
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase
EP3418383A1 (en) 2017-06-21 2018-12-26 XL-protein GmbH Modified l-asparaginase
CN110891612A (zh) 2017-06-21 2020-03-17 Xl-蛋白有限责任公司 蛋白质药物与p/a肽的缀合物
US11548931B2 (en) 2017-11-16 2023-01-10 Xl-Protein Gmbh PASylated VEGFR/PDGFR fusion proteins and their use in therapy

Also Published As

Publication number Publication date
JP2019508020A (ja) 2019-03-28
IL259352A (en) 2018-07-31
ES2877539T3 (es) 2021-11-17
EP3394266A1 (en) 2018-10-31
CN109153996A (zh) 2019-01-04
EP3919623A1 (en) 2021-12-08
US11401305B2 (en) 2022-08-02
NZ742902A (en) 2023-12-22
KR102654180B1 (ko) 2024-04-04
LT3394266T (lt) 2021-08-25
EP3394266B1 (en) 2021-04-14
AU2016378646A1 (en) 2018-06-14
SI3394266T1 (sl) 2021-08-31
BR112018012784A2 (pt) 2019-02-05
AU2016378646B2 (en) 2023-03-09
CA3005115A1 (en) 2017-06-29
KR20180088484A (ko) 2018-08-03
PL3394266T3 (pl) 2021-12-13
DK3394266T3 (da) 2021-06-07
IL259352B (en) 2022-02-01
JP7065772B2 (ja) 2022-05-12
WO2017109087A1 (en) 2017-06-29
US20190010192A1 (en) 2019-01-10
SG11201803958WA (en) 2018-07-30
HUE055267T2 (hu) 2021-11-29
CN109153996B (zh) 2022-03-25
EA201891127A1 (ru) 2019-01-31

Similar Documents

Publication Publication Date Title
MX2018007680A (es) Acidos nucleicos que codifican secuencias repetitivas de aminoacidos ricas en residuos de prolina y alanina que tienen secuencias nucleotidicas con baja repetitividad.
RU2017134456A (ru) Рекомбинантные связывающие белки и их применение
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
WO2017025179A8 (en) A transglutamine tag for efficient site-specific bioconjugation
ZA202101376B (en) Tertiary amino lipidated cationic peptides for nucleic acid delivery
WO2014202616A3 (en) Rasamsonia gene and use thereof
MX2024014468A (es) Anticuerpos anti-cd63, conjugados y usos de estos
PE20142451A1 (es) Composiciones de conjugados de xten y metodos para realizar las mismas
EP3936141A3 (en) Anti-senescence compounds and uses thereof
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
AR076977A1 (es) Proteinas precursoras repetitivas autoensambladas
NZ721544A (en) Factor viii chimeric proteins and uses thereof
UA110599C2 (uk) Пептид для імунотерапії пухлин, включаючи нейрональні пухлини та пухлини мозку
NZ757882A (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
EP4269562A3 (en) Antigen binding molecules and methods of use thereof
UA107180C2 (uk) Туберкульозний білок rv1753c, композиція, що його містить, та застосування
MX363443B (es) Proteinas de tipo espiral enrollada modificadas que tienen propiedades mejoradas.
WO2016130628A8 (en) Griffithsin mutants
PH12012502520A1 (en) Plants having enhanced yield-related traits and method for making the same
IL261112A (en) Conjugations of amino acid and peptide and conjugation process
WO2015107363A3 (en) Mycobacterial antigen composition
MX2018005411A (es) Polipeptidos anti il-23.
WO2011135222A3 (fr) Utilisation de peptides comme transporteurs destines a l'internalisation de molecules d'interet dans des cellules cibles
PE20230343A1 (es) Peptidos que estimulan respuestas inmunitarias antitumorales
MX2010005816A (es) Epítopos de péptido de stat3.